Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) has partnered with a cannabis producer, a healthcare centre and a research firm to bring a psychedelics and cannabis healthcare centre to Costa Rica.
On Tuesday, the Vancouver-based mushroom producer announced a partnership with the healthcare center Promises Innovative Recovery (PIR) which is a Florida-based Social Impact Organization that provides mental health services through its centres.
Under the agreement, Optimi and the Princeton-based cannabis producer Castle Rock Farms Inc. which is a subsidiary of BC Green Pharmaceuticals Inc. will be collaborating with PIR and the clinical research group Knowde Group, Inc. to establish a centre in Costa Rica.
The centre will focus on research and advancing techniques in psychedelic-assisted mental health treatments with cannabis and psilocybin.
The company says that the recent regulatory advancements in Costa Rica around cannabis prompted the agreement.
“The leadership of the Costa Rican government, and Promises Innovative Recovery, is an excellent chance for industry stakeholders to move forward in partnership and good faith with national health authorities,” BC Green COO Bryan Safarik said.
“It is our sincere hope that this collaboration, beginning with research and medical tourism, will lead to a more complete regulatory framework for the widespread medicinal implementation of cannabis and psychedelic therapeutics.”
BC Green is a family-operated cannabis producer that operates out of its facilities in Princeton, B.C.
Read more: Optimi receives amendment from Health Canada permitting MDMA production
Read more: Optimi Health partners with patient advocate to launch new psilocybin product
Promises Innovative Recovery co-founder Gary Roberts is meeting with Costa Rican officials and interested stakeholders this week to discuss the licensed framework.
“Our agreement with Optimi and BC Green instantly validates the quality and scale of supply required to support a future medicinal and therapeutic framework in Costa Rica,” Roberts said.
“We have an opportunity to build a clinically validated, compassionate access framework, much like the SAP model in Canada, that would put Costa Rica’s psychedelic medical tourism industry in a league of its own.”
Optimi produces EU-GMP grade psilocybin and other psychedelics. It owns a 20,000 square feet facility in Princeton, British Columbia, which makes it the largest producer of psilocybin and MDMA in North America.
